163 related articles for article (PubMed ID: 1847694)
1. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.
Endres S; Fülle HJ; Sinha B; Stoll D; Dinarello CA; Gerzer R; Weber PC
Immunology; 1991 Jan; 72(1):56-60. PubMed ID: 1847694
[TBL] [Abstract][Full Text] [Related]
2. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
[TBL] [Abstract][Full Text] [Related]
6. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides.
Renz H; Gong JH; Schmidt A; Nain M; Gemsa D
J Immunol; 1988 Oct; 141(7):2388-93. PubMed ID: 2844899
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
8. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
10. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity.
Semmler J; Gebert U; Eisenhut T; Moeller J; Schönharting MM; Alléra A; Endres S
Immunology; 1993 Apr; 78(4):520-5. PubMed ID: 8388363
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide post-transcriptionally up-regulates LPS-induced IL-8 expression through p38 MAPK activation.
Ma P; Cui X; Wang S; Zhang J; Nishanian EV; Wang W; Wesley RA; Danner RL
J Leukoc Biol; 2004 Jul; 76(1):278-87. PubMed ID: 15178710
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP increases endogenous granulocyte colony-stimulating factor formation in monocytes and THP-1 macrophages despite attenuated TNF-alpha formation.
Hareng L; Meergans T; von Aulock S; Volk HD; Hartung T
Eur J Immunol; 2003 Aug; 33(8):2287-96. PubMed ID: 12884304
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of phorbol 12-myristate 13-acetate-induced tumor necrosis factor-alpha and interleukin-1 beta production and gene expression in human monocytic cells by human alpha-fetoprotein.
Wang W; Alpert E
Hepatology; 1995 Sep; 22(3):921-8. PubMed ID: 7544757
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis.
Hart PH; Ahern MJ; Smith MD; Finlay-Jones JJ
Immunology; 1995 Apr; 84(4):536-42. PubMed ID: 7790026
[TBL] [Abstract][Full Text] [Related]
15. [Effects of DbcAMP on tumor necrosis factor and interleukin-1 production in human monocytes].
Sato W; Enzan K; Kayaba M; Masaki Y; Matsumoto J; Suzuki M
Masui; 1993 Sep; 42(9):1302-5. PubMed ID: 8230718
[TBL] [Abstract][Full Text] [Related]
16. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells.
Neuner P; Klosner G; Schauer E; Pourmojib M; Macheiner W; Grünwald C; Knobler R; Schwarz A; Luger TA; Schwarz T
Immunology; 1994 Oct; 83(2):262-7. PubMed ID: 7835945
[TBL] [Abstract][Full Text] [Related]
17. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
18. Control by IFN-gamma and PGE2 of TNF alpha and IL-1 production by human monocytes.
Hart PH; Whitty GA; Piccoli DS; Hamilton JA
Immunology; 1989 Mar; 66(3):376-83. PubMed ID: 2495247
[TBL] [Abstract][Full Text] [Related]
19. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production.
Shimozato T; Iwata M; Kawada H; Tamura N
Immunology; 1991 Apr; 72(4):497-501. PubMed ID: 1645326
[TBL] [Abstract][Full Text] [Related]
20. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
Cheng JB; Watson JW; Pazoles CJ; Eskra JD; Griffiths RJ; Cohan VL; Turner CR; Showell HJ; Pettipher ER
J Pharmacol Exp Ther; 1997 Feb; 280(2):621-6. PubMed ID: 9023272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
